Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2010. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by seven individuals on December 9, 2010, at a price of £12.49 per share through the Company's Share Reward Plan. Each individual acquired 10 shares under the partnership element and 10 shares under the matching element, though the source of contribution (personal vs. company) varied by individual.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of specific share purchases in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: December 9, 2010.
- Share Price: £12.49 per Ordinary share.
- Participants: Mr A P Witty, Mr J S Heslop, Mr S M Bicknell, Mr E J Gray, Mr D S Redfern, Ms C Thomas, and Mr P J T Vallance.
- Volume: Each participant acquired a total of 20 shares (10 partnership, 10 matching).
- Regulatory Basis: Notification made pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).